Baoxiu Liu

Title: Baoxiu Liu: Innovator in Peptide Research

Introduction

Baoxiu Liu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of peptide research, particularly in the development of peptides that interact with the PD-L1 protein. His work has implications for cancer immunotherapy, showcasing the potential to enhance immune responses against tumors.

Latest Patents

Baoxiu Liu holds a patent for a peptide having high affinity for the PD-L1 protein. The patent describes a peptide that can bind to human PD-L1 with high affinity, effectively blocking the PD-1/PD-L1 interaction. This innovative peptide can activate immune responses and increase the lethality of T cells against tumor cells. The patent includes amino acid sequences identified as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4, as well as a tandem or branched peptide with multiple repeats of these sequences.

Career Highlights

Throughout his career, Baoxiu Liu has demonstrated a commitment to advancing scientific knowledge in the field of immunology. His research has focused on the mechanisms of immune regulation and the development of therapeutic peptides. His innovative approach has led to valuable insights that could transform cancer treatment.

Collaborations

Baoxiu Liu has collaborated with Naishuo Zhu, contributing to the advancement of peptide research and its applications in immunotherapy. Their partnership has fostered a productive exchange of ideas and expertise in the field.

Conclusion

Baoxiu Liu's work in peptide research represents a significant advancement in the fight against cancer. His innovative patent and collaborative efforts highlight the importance of scientific research in developing new therapeutic strategies.